期刊
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
卷 21, 期 10, 页码 2573-2585出版社
WILEY
DOI: 10.1111/jcmm.13178
关键词
dihydroberberine; sunitinib; combination therapy; NSCLC; MAPK; anti-inflammation
资金
- National Natural Science Foundation of China [81503101, 81370088, 81227802]
- Fundamental Research Funds for the Central Universities of Zhuizong
- Project of Shaanxi Star of Science and Technology [2012Kjxx-06]
- National Science Foundation for Post-doctoral Scientists of China [2015M570843]
- Shaanxi Post-doctoral Science Foundation
- Supporting Plan of Education Ministry's New Century Excellent Talents [NCET-13-0467]
Highly effective and attenuated dose schedules are good regimens for drug research and development. Combination chemotherapy is a good strategy in cancer therapy. We evaluated the antitumour effects of dihydroberberine combined with sunitinib (DCS) on the human non-small cell lung cancer cell lines (NSCLC), A549, NCI-H460, and NCI-H1299 in vitro and in vivo. DCS showed synergic effects on NCI-H460 cell proliferation, colony formation and transplantable tumour growth, which suggested dihydroberberine increases the sensitivity of lung carcinoma to sunitinib. Further studies indicated that DCS down-regulated phosphorylation of JNK, p38, and NF-B in NCI-H460 cells and tumours and suppressed the IB and COX-2 expression. In addition, DCS reduced the secretion of the pro-inflammatory cytokine, interleukin-1 (IL-1), in tumours. Inhibition of p38 activation by DCS was a likely contributing factor in IL-1 and COX-2 down-regulation. Consistent with these results, a genomewide microarray analysis found that DCS induced the expression of cell cycle signal molecules that are known to be affected by JNK and p38. The change of cell cycle, in turn, led to down-regulation of JNK and p38, and further reduced IL-1 secretion. Collectively, these findings highlight potential molecular mechanisms of DCS chemotherapeutic activity and suggest that DCS is an efficacious strategy in NSCLC therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据